Related Experiment Video
Updated: Jul 26, 2026
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
Linomide and antibody-targeted superantigen therapy abolishes formation of liver metastases in mice
Q Liu1, D Klintman, M Corbascio
1Department of Surgery, Malmö University Hospital, Lund University, Malmö, Sweden.
Abstract:
Hematogenous spread of tumor cells and metastasis formation in the liver are insidious aspects of cancer progression and are not frequently amenable to curative treatment. We examined the effect of Linomide and antibody-targeted therapy against the formation of hepatic metastases in vivo. For this purpose, syngenic B16 melanoma cells transfected with GA733-2 (a human colon cancer cell surface antigen) were injected into a mesenteric vein of C57/Bl6 mice. To test bacterial superantigen (Sag) targeting for immunotherapy of liver metastases, we used genetically fused proteins consisting of SEA and a Fab moiety of a GA733-2 tumor-reactive antibody (C215Fab-SEA). Linomide dose-dependently reduced hepatic metastases, and at 300 mg/kg this reduction was more than 80%. Treatment with C215Fab-SEA decreased metastases formation by 49% and the combination of Linomide and C215Fab-SEA was found to completely abolish liver metastases (>99% reduction). Taken together, our novel data suggest that Linomide and antibody-targeted superantigen therapy individually markedly reduce and together abolish liver metastases. Considering that current therapy of hepatic metastases is mainly limited to surgical resection in a subgroup of patients, these findings indicate that Linomide alone or in combination with antibody-targeted superantigen may provide a novel approach against liver metastases.
Insights
Linomide and antibody-targeted superantigen therapy significantly reduce liver metastases. Combining these treatments completely abolished liver metastases in a mouse model, offering a potential new approach for cancer treatment.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Liver metastases are a significant challenge in cancer treatment, often lacking effective curative options.
- Hematogenous spread of tumor cells to the liver is a common and difficult-to-treat aspect of cancer progression.
Purpose of the Study:
- To investigate the efficacy of Linomide and antibody-targeted superantigen therapy in preventing hepatic metastases.
- To evaluate the combined effect of Linomide and C215Fab-SEA on liver metastasis formation in vivo.
Main Methods:
- Syngenic B16 melanoma cells expressing GA733-2 were injected into the mesenteric vein of C57/Bl6 mice.
- Treatment groups received Linomide, C215Fab-SEA (a fusion protein of SEA and a GA733-2 reactive antibody), or a combination of both.
Main Results:
- Linomide demonstrated dose-dependent reduction of hepatic metastases, with over 80% reduction at 300 mg/kg.
- C215Fab-SEA treatment reduced metastases formation by 49%.
- The combination therapy of Linomide and C215Fab-SEA resulted in a complete abolition of liver metastases (>99% reduction).
Conclusions:
- Linomide and antibody-targeted superantigen therapy show significant individual efficacy in reducing liver metastases.
- Combined treatment completely abolishes liver metastases, suggesting a novel therapeutic strategy.
- These findings offer a promising new approach for managing liver metastases, particularly where surgical options are limited.
